C
Christopher D. Lao
Researcher at University of Michigan
Publications - 127
Citations - 24365
Christopher D. Lao is an academic researcher from University of Michigan. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 35, co-authored 100 publications receiving 17710 citations.
Papers
More filters
Journal ArticleDOI
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,Marcus O. Butler,Andrew F. Hill,Ivan Marquez-Rodas,John B. A. G. Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski,Matteo S. Carlino,Céleste Lebbé,Grant A. McArthur,Paolo A. Ascierto,Gregory A. Daniels,Georgina V. Long,Tuba Bas,Corey Ritchings,James Larkin,F. Stephen Hodi +28 more
TL;DR: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolaumab alone versus IPILimumab as discussed by the authors.
Journal ArticleDOI
Features Predicting Sentinel Lymph Node Positivity in Merkel Cell Carcinoma
Jennifer L. Schwartz,Kent A. Griffith,Lori Lowe,Sandra L. Wong,Scott A. McLean,Douglas R. Fullen,Christopher D. Lao,James A. Hayman,Carol R. Bradford,Riley S. Rees,Timothy M. Johnson,Christopher K. Bichakjian +11 more
TL;DR: Increasing clinical size, increasing tumor thickness, increasing mitotic rate, and infiltrative tumor growth pattern were significantly associated with a greater likelihood of a positive SLN.
Journal ArticleDOI
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L. Topalian,Shailender Bhatia,Asim Amin,Ragini R. Kudchadkar,William H. Sharfman,Céleste Lebbé,Jean Pierre Delord,Lara Dunn,Michi M. Shinohara,Rima M. Kulikauskas,Christine H. Chung,Uwe M. Martens,Robert L. Ferris,Julie E. Stein,Elizabeth L. Engle,Lot A. Devriese,Christopher D. Lao,Junchen Gu,Bin Li,Tian Chen,Adam Barrows,Andrea Horvath,Janis M. Taube,Paul Nghiem +23 more
TL;DR: Nivolumab administered approximately 4 weeks before surgery in MCC was generally tolerable and induced pCRs and radiographic tumor regressions in approximately one half of treated patients, and early markers of response significantly predicted improved RFS.
Journal ArticleDOI
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
Hussein Abdul-Hassan Tawbi,Peter A. Forsyth,Alain Algazi,Omid Hamid,F. Stephen Hodi,Stergios J. Moschos,Nikhil I. Khushalani,Rene Gonzalez,Christopher D. Lao,Michael A. Postow,Michael B. Atkins,Marc S. Ernstoff,Igor Puzanov,Ragini R. Kudchadkar,Reena Thomas,Ahmad A. Tarhini,Joel Jiang,Alexandre Avila,Sheena Demelo,Kim Margolin +19 more
TL;DR: The first efficacy data in MEL patients (pts) with BMts who received NIVO+IPI in study CheckMate 204 are reported, and updated safety for 75 pts with disease assessment before the Nov 2016 database lock is reported.
Journal ArticleDOI
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson,Hussein Abdul-Hassan Tawbi,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,Juliana Janoski de Menezes,Stéphane Dalle,Ana Arance,Jean-Jacques Grob,Shivani Srivastava,Mena Abaskharoun,Katy L. Simonsen,Bin Li,Georgina V. Long,F. Stephen Hodi +18 more
TL;DR: A novel approach is needed to optimize the benefit-risk profile of immune checkpoint inhibitor therapy in patients with advanced melanoma by developing novel combinations of these medicines.